Data indicate significant phenotypic and genotypic overlap, plus a common pathogenesis,
between two groups of inherited disorders, autosomal dominant polycystic kidney diseases …

Autosomal-dominant polycystic kidney disease (ADPKD) affects up to 12 million individuals
and is the fourth most common cause for renal replacement therapy worldwide. There have …

Abstract Recently, the European Medicines Agency approved the use of the vasopressin V2
receptor antagonist tolvaptan to slow the progression of cyst development and renal …

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited
cause of kidney failure, accounting for 5%-10% of cases. Predicting which patients with …

Autosomal dominant polycystic kidney disease is a genetic disorder associated with
substantial variability in its natural course within and between affected families …

The clinical use of conventional ultrasonography (US) in autosomal dominant polycystic
kidney disease (ADPKD) is currently limited by reduced diagnostic sensitivity, especially in …

Renal disease variability in autosomal dominant polycystic kidney disease (ADPKD) is
strongly influenced by the gene locus (PKD1 versus PKD2). Recent studies identified …

Background and objectives ADPKD is erroneously perceived as a not rare condition, which
is mainly due to the repeated citation of a mistaken interpretation of old epidemiological …

Autosomal dominant polycystic kidney disease (ADPKD) is a common nephropathy caused
by mutations in either PKD1 or PKD2. Mutations in PKD1 account for∼ 85% of cases and …

The natural history of autosomal dominant polycystic kidney disease (ADPKD) is
characterized by a variable rate of cyst development and increase in total kidney volume …